Method for treating SARS-COV-2 infectious disease
Disclosed are a composition for diagnosis of SARS-CoV-2 infectious disease, a diagnostic kit, a method for providing information for diagnosis, a method for screening a therapeutic agent, and a composition for prevention or treatment, wherein it is expected that the diagnosis or prognostic prediction of the severity of SARS-CoV-2 infectious disease can be attained and the control of expression and activity of TOX, which is a marker, can be advantageously used in the development of a therapeutic agent for SARS-CoV-2 infectious disease.
1 . A method for treating SARS-CoV-2 infectious disease accompanied by sepsis or acute respiratory distress syndrome (ARDS) in a subject in need thereof, the method comprising
administering to the subject a therapeutically effective amount of a TOX-directed inhibitory agent selected from the group consisting of: (i) an antibody or antigen-binding fragment that specifically binds thymocyte selection-associated high mobility group box (TOX) protein comprising SEQ ID NO: 1; and (ii) an siRNA or shRNA that specifically hybridizes to a polynucleotide comprising SEQ ID NO: 2 encoding human TOX.
2 . A method for treating a patient infected with SARS-CoV-2 and accompanied by sepsis or acute respiratory distress syndrome (ARDS), the method comprising:
obtaining a biological sample from the patient;
measuring TOX protein level or TOX mRNA expression level in the biological sample;
comparing the measured TOX protein level or TOX mRNA expression level with that of a normal control group;
determining that the measured TOX protein level or TOX mRNA expression level is at least two-fold higher than that of the normal control group; and
administering to the patient a therapeutically effective amount of a TOX-directed inhibitory agent selected from the group consisting of: (i) an antibody or antigen-binding fragment that specifically binds thymocyte selection-associated high mobility group box (TOX) protein comprising SEQ ID NO: 1; and (ii) an siRNA or shRNA that specifically hybridizes to a polynucleotide comprising SEQ ID NO: 2 encoding human TOX.
3 . The method of claim 2 , wherein the biological sample is at least one selected from the group consisting of blood, plasma, serum, saliva, nasal mucus, sputum, capsular fluid, amniotic fluid, ascites, cervical or vaginal discharge, urine, and cerebrospinal fluid.